参令白术粉通过调节高脂肪饮食诱导的大鼠自噬和能量代谢来缓解非酒精性脂肪肝疾病。
Shenling Baizhu powder alleviates non-alcoholic fatty liver disease by modulating autophagy and energy metabolism in high-fat diet-induced rats.
机构信息
School of Traditional Chinese Medicine, Jinan University, Guangzhou 510632, Guangdong Province, China.
School of Traditional Chinese Medicine, Jinan University, Guangzhou 510632, Guangdong Province, China; Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518033, Guangdong Province, China.
出版信息
Phytomedicine. 2024 Jul 25;130:155712. doi: 10.1016/j.phymed.2024.155712. Epub 2024 May 4.
BACKGROUND
Non-alcoholic fatty liver disease (NAFLD) has emerged as a burgeoning health problem worldwide, but no specific drug has been approved for its treatment. Shenling Baizhu powder (SL) is extensively used to treat NAFLD in Chinese clinical practice. However, the therapeutic components and pharmacological mechanisms of SL against NAFLD have not been thoroughly investigated.
PURPOSE
This study aimed to investigate the pharmacological impact and molecular mechanism of SL on NAFLD.
METHODS
First, we established an animal model of NAFLD by high-fat diet (HFD) feeding, and evaluated the therapeutic efficacy of SL on NAFLD by physiological, biochemical, pathological, and body composition analysis. Next, the effect of SL on autophagic flow in NAFLD rats was evaluated by ultrastructure, immunofluorescence staining, and western blotting. Moreover, an integrated strategy of targeted energy metabolomics and network pharmacology was performed to characterize autophagy-related genes and explore the synergistic effects of SL active compounds. UPLC-MS/MS, molecular docking combined with in vivo and in vitro experiments were conducted to verify the key compounds and genes. Finally, a network was established among SL-herb-compound-genes-energy metabolites-NAFLD, which explains the complicated regulating mechanism of SL on NAFLD.
RESULTS
We discovered that SL decreased hepatic lipid accumulation, hepatic steatosis, and insulin resistance, and improved systemic metabolic disorders and pathological abnormalities. Subsequently, an integrated strategy of targeted energy metabolomics and network pharmacology identified quercetin, ellagic acid, kaempferol, formononetin, stigmasterol, isorhamnetin and luteolin as key compounds; catalase (CAT), AKT serine/threonine kinase 1 (AKT), nitric oxide synthase 3 (eNOS), NAD(P)H quinone dehydrogenase 1 (NQO1), heme oxygenase 1 (HO-1) and hypoxia-inducible factor 1 subunit alpha (HIF-1α) were identified as key genes; while nicotinamide adenine dinucleotide phosphate (NADP) and succinate emerged as key energy metabolites. Mechanistically, we revealed that SL may exert its anti-NAFLD effect by inducing autophagy activation and forming a comprehensive regulatory network involving key compounds, key genes, and key energy metabolites, ultimately alleviating oxidative stress, endoplasmic reticulum stress, and mitochondrial dysfunction.
CONCLUSION
Our study demonstrated the therapeutic effect of SL in NAFLD models, and establishes a basis for the development of potential products from SL plant materials for the treatment of NAFLD.
背景
非酒精性脂肪性肝病(NAFLD)已成为全球日益严重的健康问题,但尚无特定药物被批准用于其治疗。参苓白术散(SL)在中国临床实践中广泛用于治疗 NAFLD。然而,SL 对 NAFLD 的治疗成分和药理机制尚未得到充分研究。
目的
本研究旨在探讨 SL 对 NAFLD 的药理作用及分子机制。
方法
首先,我们通过高脂饮食(HFD)喂养建立了 NAFLD 动物模型,并通过生理、生化、病理和体成分分析评估 SL 对 NAFLD 的治疗效果。接下来,通过超微结构、免疫荧光染色和 Western blot 评估 SL 对 NAFLD 大鼠自噬流的影响。此外,采用靶向能量代谢组学和网络药理学的综合策略,对与自噬相关的基因进行特征描述,并探讨 SL 活性化合物的协同作用。采用 UPLC-MS/MS、分子对接结合体内和体外实验,验证关键化合物和基因。最后,建立 SL-草药-化合物-基因-能量代谢物-NAFLD 网络,解释 SL 对 NAFLD 的复杂调节机制。
结果
我们发现 SL 可减少肝脂质堆积、肝脂肪变性和胰岛素抵抗,并改善全身代谢紊乱和病理异常。随后,采用靶向能量代谢组学和网络药理学的综合策略,鉴定出槲皮素、鞣花酸、山奈酚、芒柄花素、豆甾醇、异鼠李素和木樨草素为关键化合物;过氧化氢酶(CAT)、蛋白激酶 B(AKT)、一氧化氮合酶 3(eNOS)、烟酰胺腺嘌呤二核苷酸磷酸(NADP)醌脱氢酶 1(NQO1)、血红素加氧酶 1(HO-1)和缺氧诱导因子 1 亚基α(HIF-1α)为关键基因;而烟酰胺腺嘌呤二核苷酸(NAD)和琥珀酸则为关键能量代谢物。在机制上,我们揭示 SL 可能通过诱导自噬激活来发挥其抗 NAFLD 作用,并形成一个包含关键化合物、关键基因和关键能量代谢物的综合调控网络,从而减轻氧化应激、内质网应激和线粒体功能障碍。
结论
本研究证实了 SL 在 NAFLD 模型中的治疗效果,并为 SL 植物材料开发治疗 NAFLD 的潜在产品奠定了基础。